Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 8000 Marina Boulevard,, Suite 120 BRISBANE CA 94005 |
Tel: | N/A |
Website: | https://veratx.com |
IR: | See website |
Key People | ||
Marshall Fordyce President, Chief Executive Officer, Founder, Director | Sean P. Grant Chief Financial Officer | Robert M. Brenner Chief Medical Officer | William D. Turner Chief Development Officer |
Business Overview |
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants. The Company is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which it refers to as ORIGIN 3, and completing the open label extension of its Phase 2b clinical trial in IgAN, which it refers to as ORIGIN 2b. |
Financial Overview |
For the three months ended 31 March 2024, Vera Therapeutics Inc revenues was not reported. Net loss decreased 6% to $28.4M. Lower net loss reflects Research and development - Balancing val decrease of 22% to $15.5M (expense), Interest Income increase from $1.6M to $4.2M (income), Other income increase of 3% to $453K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.80 to -$0.56. |
Employees: | 55 as of Mar 31, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,971M as of Mar 31, 2024 |
Annual revenue (TTM): | $0.00M as of Mar 31, 2024 |
EBITDA (TTM): | -$101.87M as of Mar 31, 2024 |
Net annual income (TTM): | -$94.30M as of Mar 31, 2024 |
Free cash flow (TTM): | -$99.78M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 54,701,217 as of May 3, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |